Ten-Year Outcomes of Children and Adolescents Who Underwent Sleeve Gastrectomy: Weight Loss, Comorbidity Resolution, Adverse Events, and Growth Velocity

Infographic · Apr 2022 · 1 min read

In brief

This 10-year prospective study of 2,504 pediatric patients demonstrates that laparoscopic sleeve gastrectomy produces sustained weight loss (71% excess weight lost at 7-10 years) and high rates of comorbidity remission without compromising growth velocity. With only 1% adverse events and no mortality, LSG appears safe and effective for severe pediatric obesity.

LSG in pediatric patients achieved 71% excess weight loss at 7-10 years, demonstrating durable long-term efficacy beyond typical 5-year studies
Complete remission of type 2 diabetes (74%), dyslipidemia (59%), and hypertension (64%) was maintained at long-term follow-up
Growth velocity remained unaffected with no significant height z-score change across 10 years of follow-up
Adverse event rate was remarkably low at 1% (27/2,504 patients) with zero procedure-related mortality
Multidisciplinary family-based approach combined with LSG provides safe, effective treatment for severe pediatric obesity ages 5-21

Written by the GCMD Library team from the infographic.

The infographic uses a clean layout with a red header banner and three main columns below. On the left is a gray silhouette of a person with a stomach diagram, accompanied by study details. The three right columns display outcomes using icons: a scale with footprints for weight loss, a hand with heart for comorbidity remission, and a height chart for growth velocity. Blue accent colors highlight key statistics.

Background: To date, there are insufficient data on long-term outcomes of weight loss surgery in children and adolescents with obesity beyond 5 years of follow-up. This study aimed to analyze durability of weight loss and comorbidity resolution, growth velocity, and adverse events associated with laparoscopic sleeve gastrectomy (LSG) in children and adolescents with severe obesity.

Study design: In this prospective cohort study, 2,504 children and adolescents with class II/III obesity who were enrolled in a multidisciplinary, family-based pediatric obesity management program underwent LSG between 2008 and 2021. Weight loss, growth, comorbidity resolution, and adverse event data during the first 10 years after LSG were analyzed.

Results: The cohort age was 5 to 21 years at the time of operation, and 55% were female. Mean ± SD percentage of excess weight lost during short- (1 to 3 years; n = 2,051), medium- (4 to 6 years; n = 1,268), and long-term (7 to 10 years; n = 632) follow-up was 82.3% ± 20.5%, 76.3% ± 29.1%, and 71.1% ± 26.9%, respectively. Complete comorbidity remission at long-term follow-up was observed in 74%, 59%, and 64% of type 2 diabetes, dyslipidemia, and hypertension cases, respectively. Mean ± SD height z-score change at short-, medium-, and long-term follow-up was 0.1 ± 0.5, 0.1 ± 1.2, and 0.0 ± 0.8, respectively, representing no significant change in growth velocity. There were 27 adverse events (1%) with no procedure-related mortality.

Conclusions: Long-term follow-up after LSG in children and adolescents demonstrates durable weight loss, maintained comorbidity resolution, and unaltered growth.

The text in the image

Read it at the source ↗